The global dasatinib market size was estimated at USD 5.59 billion in 2025 and is projected to reach USD 7.57 billion by 2033, growing at a CAGR of 4.27% from 2026 to 2033. The global dasatinib market is expanding due to the rising prevalence of hematologic malignancies, particularly chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia.
Increasing awareness of targeted oncology therapies has improved diagnosis and early treatment initiation across developed and emerging regions. Physicians prefer tyrosine kinase inhibitors for sustained disease control, supporting long term demand. Longer survival has increased cumulative drug utilization, strengthening revenue visibility. For instance, November 2025, OncLive reported FDA approval of a generic dasatinib abbreviated new drug application in six strengths, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Initial clearance occurred in 2006, with expansion in January 2019 based on a phase 2 trial in 78 pediatric patients showing 64.1 percent 3 year event free survival, 95 percent confidence interval 52.4 percent to 74.7 percent, 96 percent below 5 percent marrow blasts at induction, 97 percent at consolidation, 4 percent fatal adverse effects among 81 patients, and 10 percent discontinuation.
Advancements in precision medicine and molecular diagnostics have strengthened biomarker driven therapy selection, accelerating adoption of targeted treatments such as dasatinib. Clinical evidence in resistant or intolerant chronic myeloid leukemia has reinforced physician confidence and supported guideline recommendations for second generation tyrosine kinase inhibitors. For instance, January 2026, Cancer Reports published a retrospective analysis of 53 adults treated with low dose dasatinib 50 mg daily between 2002 and 2025, with a median age of 50 years. Molecular response outcomes included 41.5 percent achieving MR4.5, 20.8 percent MR4.0, and 15.1 percent major molecular response without deep response. Tyrosine kinase domain mutations were present in 32.1 percent, clinically significant adverse events in 49.1 percent, 22.6 percent required switching for inadequate response, and 7.5 percent for intolerance. Baseline BCR ABL1 greater than or equal to 100 percent, T315I mutation, and high ELTS risk predicted poorer outcomes.
This product will be delivered within 1-3 business days.
Increasing awareness of targeted oncology therapies has improved diagnosis and early treatment initiation across developed and emerging regions. Physicians prefer tyrosine kinase inhibitors for sustained disease control, supporting long term demand. Longer survival has increased cumulative drug utilization, strengthening revenue visibility. For instance, November 2025, OncLive reported FDA approval of a generic dasatinib abbreviated new drug application in six strengths, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Initial clearance occurred in 2006, with expansion in January 2019 based on a phase 2 trial in 78 pediatric patients showing 64.1 percent 3 year event free survival, 95 percent confidence interval 52.4 percent to 74.7 percent, 96 percent below 5 percent marrow blasts at induction, 97 percent at consolidation, 4 percent fatal adverse effects among 81 patients, and 10 percent discontinuation.
Advancements in precision medicine and molecular diagnostics have strengthened biomarker driven therapy selection, accelerating adoption of targeted treatments such as dasatinib. Clinical evidence in resistant or intolerant chronic myeloid leukemia has reinforced physician confidence and supported guideline recommendations for second generation tyrosine kinase inhibitors. For instance, January 2026, Cancer Reports published a retrospective analysis of 53 adults treated with low dose dasatinib 50 mg daily between 2002 and 2025, with a median age of 50 years. Molecular response outcomes included 41.5 percent achieving MR4.5, 20.8 percent MR4.0, and 15.1 percent major molecular response without deep response. Tyrosine kinase domain mutations were present in 32.1 percent, clinically significant adverse events in 49.1 percent, 22.6 percent required switching for inadequate response, and 7.5 percent for intolerance. Baseline BCR ABL1 greater than or equal to 100 percent, T315I mutation, and high ELTS risk predicted poorer outcomes.
Global Dasatinib Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global dasatinib market report based on drug type, indication, distribution channel, and region:Drug Type Outlook (Revenue, USD Million, 2021-2033)
- Branded
- Generic
Indication Outlook (Revenue, USD Million, 2021-2033)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphoblastic Leukemia (ALL)
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Specialty Oncology Pharmacies
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Dasatinib Market Variables, Trends, & Scope
Chapter 4. Dasatinib Market: Drug Type Business Analysis
Chapter 5. Dasatinib Market: Indication Business Analysis
Chapter 6. Dasatinib Market: Distribution Channel Business Analysis
Chapter 7. Dasatinib Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Bristol-Myers Squibb Company
- Teva Pharmaceutical Industries Ltd.
- Sandoz Group AG
- Sun Pharmaceutical Industries Limited
- Hetero Drugs Limited
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories Limited
- Intas Pharmaceuticals Ltd.
- Cipla Limited
- Lupin Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 5.59 Billion |
| Forecasted Market Value ( USD | $ 7.57 Billion |
| Compound Annual Growth Rate | 4.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
